A detailed history of Knoll Capital Management, LLC transactions in Biohaven Pharmaceutical Holding CO Ltd. stock. As of the latest transaction made, Knoll Capital Management, LLC holds 710,422 shares of BHVN stock, worth $37.7 Million. This represents 16.66% of its overall portfolio holdings.

Number of Shares
710,422
Previous 490,422 44.86%
Holding current value
$37.7 Million
Previous $26.8 Million 8.06%
% of portfolio
16.66%
Previous 16.74%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$32.77 - $53.49 $7.21 Million - $11.8 Million
220,000 Added 44.86%
710,422 $24.7 Million
Q3 2023

Nov 14, 2023

BUY
$16.93 - $26.41 $677,200 - $1.06 Million
40,000 Added 8.88%
490,422 $12.8 Million
Q4 2022

Feb 14, 2023

SELL
$7.0 - $16.87 $3.15 Million - $7.6 Million
-450,422 Reduced 50.0%
450,422 $6.25 Million
Q1 2022

May 16, 2022

BUY
$110.08 - $142.92 $440,320 - $571,680
4,000 Added 0.45%
900,844 $107 Million
Q4 2021

Feb 14, 2022

BUY
$99.73 - $148.48 $3.99 Million - $5.94 Million
40,000 Added 4.67%
896,844 $124 Million
Q1 2021

Jun 14, 2021

SELL
$64.07 - $91.75 $41,645 - $59,637
-650 Reduced 0.08%
856,844 $58.6 Million
Q3 2019

Nov 14, 2019

BUY
$37.38 - $49.47 $4.03 Million - $5.33 Million
107,679 Added 14.36%
857,494 $35.8 Million
Q1 2018

May 15, 2018

SELL
$22.49 - $34.56 $1.29 Million - $1.98 Million
-57,409 Reduced 7.11%
749,815 $19.3 Million
Q3 2017

Nov 14, 2017

BUY
$23.54 - $38.21 $19 Million - $30.8 Million
807,224
807,224 $30.2 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Knoll Capital Management, LLC Portfolio

Follow Knoll Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knoll Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Knoll Capital Management, LLC with notifications on news.